Kestra Medical Technologies (NASDAQ:KMTS) Posts Earnings Results, Misses Estimates By $0.01 EPS

Kestra Medical Technologies (NASDAQ:KMTS) posted its quarterly earnings results on Tuesday. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.01), FiscalAI reports. The company had revenue of $24.55 million for the quarter. The firm’s revenue was up 62.7% compared to the same quarter last year.

Kestra Medical Technologies Stock Performance

Shares of NASDAQ:KMTS opened at $21.14 on Wednesday. The firm has a 50 day moving average of $24.33 and a 200 day moving average of $24.57. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $1.23 billion and a price-to-earnings ratio of -6.67. Kestra Medical Technologies has a 52 week low of $13.25 and a 52 week high of $30.00.

Insider Buying and Selling at Kestra Medical Technologies

In other news, insider Traci S. Umberger sold 10,500 shares of Kestra Medical Technologies stock in a transaction on Monday, December 29th. The stock was sold at an average price of $26.69, for a total value of $280,245.00. Following the transaction, the insider directly owned 136,633 shares in the company, valued at approximately $3,646,734.77. This trade represents a 7.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $25.60, for a total value of $384,000.00. Following the completion of the transaction, the insider directly owned 379,786 shares of the company’s stock, valued at approximately $9,722,521.60. The trade was a 3.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 55,500 shares of company stock worth $1,405,095 in the last ninety days. Insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Kestra Medical Technologies

A number of large investors have recently added to or reduced their stakes in KMTS. Invesco Ltd. bought a new stake in shares of Kestra Medical Technologies in the 4th quarter valued at about $239,000. Perceptive Advisors LLC bought a new position in shares of Kestra Medical Technologies during the 4th quarter worth approximately $7,558,000. Janus Henderson Group PLC purchased a new stake in Kestra Medical Technologies during the fourth quarter valued at approximately $300,000. Balyasny Asset Management L.P. boosted its stake in Kestra Medical Technologies by 80.6% in the fourth quarter. Balyasny Asset Management L.P. now owns 6,915 shares of the company’s stock valued at $183,000 after acquiring an additional 3,086 shares in the last quarter. Finally, Burkehill Global Management LP purchased a new position in Kestra Medical Technologies in the fourth quarter worth $1,326,000.

Wall Street Analysts Forecast Growth

KMTS has been the subject of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Wednesday, December 24th. The Goldman Sachs Group set a $24.00 price target on shares of Kestra Medical Technologies in a research note on Friday, January 16th. Stifel Nicolaus set a $30.00 price target on Kestra Medical Technologies in a report on Friday, December 12th. BTIG Research restated a “buy” rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday. Finally, Wells Fargo & Company lifted their target price on Kestra Medical Technologies from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.00.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.